Strategic Partners (1TB0) 주식 개요전략적 파트너 A/S는 큰 규모의 운영을 하지 않습니다. 자세히 보기1TB0 펀더멘털 분석스노우플레이크 점수가치 평가4/6미래 성장0/6과거 실적2/6재무 건전성6/6배당0/6강점공정 가치 추정치보다 낮은 79.9% 에서 거래올해부터 흑자전환위험 분석수익이 USD$1m 미만입니다(DKK304K)의미 있는 시가총액이 없습니다(€4M)재무 결과에 영향을 미치는 대규모 일회성 항목모든 위험 점검 보기1TB0 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW466,960 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA466,960 investors already sharing narrativesYour Fair Value€Current Price€92.00199.9k% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-437m1m2016201920222025202620282031Revenue DKK 193.8Earnings DKK 858.7AdvancedSet Fair ValueView all narrativesStrategic Partners A/S 경쟁사2investSymbol: XTRA:2INVMarket cap: €62.9mNovogeniaSymbol: MUN:7V0Market cap: €69.6mCapForceSymbol: OTCPK:CFORMarket cap: US$49.5mNirman Agri GeneticsSymbol: NSEI:NIRMANMarket cap: ₹232.7m가격 이력 및 성과Strategic Partners 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가DKK 92.0052주 최고가DKK 133.5052주 최저가DKK 69.00베타0.281개월 변동3.37%3개월 변동24.32%1년 변동-31.34%3년 변동-37.33%5년 변동-97.98%IPO 이후 변동-98.50%최근 뉴스 및 업데이트Board Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Jakob Have was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공고 • Nov 25Strategic Partners A/S, Annual General Meeting, Apr 28, 2026Strategic Partners A/S, Annual General Meeting, Apr 28, 2026, at 10:00 Romance Standard Time.공고 • Sep 17Strategic Partners A/S Revises Earnings Guidance for the Fiscal Year 2025Strategic Partners A/S revised earnings guidance for the fiscal year 2025. Based on the first half of the year the company changes its outlook from previously an operating loss in the range of DKK -3 to -4 million to DKK -2 to -3 million.공고 • Jan 10Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP).Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025. As part of acquisition, 2,327,058 shares were acquired. Stockslatten AB completed the acquisition of 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025.공고 • Dec 27Strategic Partners A/S, Annual General Meeting, Mar 26, 2025Strategic Partners A/S, Annual General Meeting, Mar 26, 2025.New Risk • Sep 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€6.71m market cap, or US$7.47m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).더 많은 업데이트 보기Recent updatesBoard Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Jakob Have was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공고 • Nov 25Strategic Partners A/S, Annual General Meeting, Apr 28, 2026Strategic Partners A/S, Annual General Meeting, Apr 28, 2026, at 10:00 Romance Standard Time.공고 • Sep 17Strategic Partners A/S Revises Earnings Guidance for the Fiscal Year 2025Strategic Partners A/S revised earnings guidance for the fiscal year 2025. Based on the first half of the year the company changes its outlook from previously an operating loss in the range of DKK -3 to -4 million to DKK -2 to -3 million.공고 • Jan 10Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP).Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025. As part of acquisition, 2,327,058 shares were acquired. Stockslatten AB completed the acquisition of 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025.공고 • Dec 27Strategic Partners A/S, Annual General Meeting, Mar 26, 2025Strategic Partners A/S, Annual General Meeting, Mar 26, 2025.New Risk • Sep 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€6.71m market cap, or US$7.47m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).New Risk • Sep 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (€5.02m market cap, or US$5.62m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding).New Risk • Mar 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€5.68m market cap, or US$6.13m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).Board Change • Mar 11No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Jakob Have is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.공고 • Feb 22Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024. Orphazyme informed CombiGene that they in total have acquired approximately 10% of the outstanding shares in CombiGene, which makes Orphazyme one of the larger shareholders in the Company. Orphazyme A/S (CPSE:ORPHA) completed the acquisition of an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024.공고 • May 31+ 2 more updatesOrphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFOOrphazyme A/S announced that the board of directors and CFO Anders Fink Vadsholt has entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023.공고 • May 18Orphazyme A/S Announces Board ChangesOrphazyme A/S announced that during the Annual General Meeting on May 17, 2023, Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacy as members of the Board of Directors. Michael Schlomo Gabriely Hove, Jakob Færch Bendtsen and Jakob Alsted Have were elected as new members of the Board of Directors by the general meeting.공고 • Dec 06+ 1 more updateOrphazyme A/S to Report Fiscal Year 2022 Final Results on Mar 28, 2023Orphazyme A/S announced that they will report fiscal year 2022 final results on Mar 28, 2023공고 • Sep 26Orphazyme A/S Revises Earnings Guidance for the Year 2022Orphazyme A/S revised earnings guidance for the year 2022. The Company has decided to adjust its outlook for 2022, as published on June 7, 2022. The change is driven by the separation of activities into continuing and discontinued operations. The discontinued activities are related to the sale of assets to KemPharm A/S. The continuing business activities are the limited ongoing operational business activities with only two employees. For the full-year 2022, the company anticipates a loss from continuing operations in the range DKK 40 – 45 million and a positive result from discontinued operations relating to the Sale of Assets to KemPharm of DKK 87.4 million (previously operating profit in the range DKK 10 – 30 million).Breakeven Date Change • Mar 01Forecast to breakeven in 2024The 3 analysts covering Orphazyme expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr.46.7m in 2024. Average annual earnings growth of 58% is required to achieve expected profit on schedule.Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 4 analysts covering Orphazyme expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr.187.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Executive Departure • Jul 06Independent Director Martijn Kleijwegt has left the companyOn the 30th of June, Martijn Kleijwegt's tenure as Independent Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Martijn's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.Executive Departure • Jul 06Independent Director Remi P. Droller has left the companyOn the 30th of June, Remi P. Droller's tenure as Independent Director ended after 6.5 years in the role. We don't have any record of a personal shareholding under Remi P.'s name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.Executive Departure • Jul 06Independent Director Anders Hedegaard has left the companyOn the 30th of June, Anders Hedegaard's tenure as Independent Director ended after 3.6 years in the role. As of March 2021, Anders still personally held 15.68k shares (€177k worth at the time). A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.Executive Departure • Mar 27Independent Director has left the companyOn the 25th of March, Sten Verland's tenure as Independent Director ended after 10.3 years in the role. We don't have any record of a personal shareholding under Sten's name. A total of 2 executives have left over the last 12 months.Is New 90 Day High Low • Jan 14New 90-day high: €10.56The company is up 12% from its price of €9.46 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period.Is New 90 Day High Low • Dec 15New 90-day low: €7.41The company is down 33% from its price of €10.98 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 21New 90-day low: €8.67The company is down 37% from its price of €13.76 on 23 July 2020. The German market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.공고 • Sep 30Orphazyme A/S has completed a Follow-on Equity Offering in the amount of $83.777606 million.Orphazyme A/S has completed a Follow-on Equity Offering in the amount of $83.777606 million. Security Name: American Depositary Share Security Type: Depositary Receipt (Common Stock) Securities Offered: 3,966,146 Price\Range: $11 Discount Per Security: $0.77 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,650,000 Price\Range: $11 Discount Per Security: $0.77 Transaction Features: New Market Listing; Sponsor Backed Offering공고 • Sep 26Orphazyme A/S Provides Update on Previously Announced Global OfferingOrphazyme A/S announced an update on its previously announced global offering. On September 24, 2020, the Company received a filing communication from the U.S. Food and Drug Administration in connection with its new drug application for arimoclomol for the treatment of Niemann-Pick disease Type C. The FDA letter follows acceptance on a Priority Review basis by the FDA of the Company’s NDA for arimoclomol in NPC and the FDA’s establishment of the Prescription Drug User Fee Act target action date of March 17, 2021. The Company’s receipt of the filing communication does not impact the FDA’s acceptance of the Company’s NDA, the target PDUFA action date or the FDA’s Priority Review determination. In accordance with applicable securities laws, the Company intends to amend the registration statement on Form F-1 on file with the U.S. Securities and Exchange Commission on September 25, 2020. The Company has also updated its proposed timing for the global offering referenced in the company announcement no. 51/2020, dated September 21, 2020, and now intends to price the global offering and announce the subscription price on September 28, 2020, subject to market conditions, and to settle the global offering on October 1, 2020. The Company also reported that the book for the global offering is fully covered as of September 24, 2020. The ordinary shares of the Company are currently listed on Nasdaq Copenhagen under the symbol ”ORPHA”. In connection with the global offering, Nasdaq has approved the listing of the American Depositary Shares in the U.S. under the symbol "ORPH". A registration statement on Form F-1 relating to the proposed sale of the Securities has been filed with the SEC but has not yet become effective. The Securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement on Form F-1 becomes effective. The Board has not yet determined whether to complete the global offering. Even if the Board determines to complete the global offering, the global offering may not be consummated. Neither the timing, number of shares, number of ordinary underlying shares of Orphazyme, nor the price of the ADSs and thereby the price of the underlying shares has been finally determined. If consummated, the final price for the ordinary shares and ADSs will be determined following a book-building process.Is New 90 Day High Low • Sep 26New 90-day low: €9.92The company is down 18% from its price of €12.14 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.공고 • Sep 22Orphazyme A/S Elects Carrolee Barlow as Board of DirectorOrphazyme A/S elected Carrolee Barlow as new member of the Board of Directors, Extraordinary General Meeting held on September 21, 2020.주주 수익률1TB0DE BiotechsDE 시장7D-2.1%-4.7%-0.6%1Y-31.3%-1.0%2.7%전체 주주 수익률 보기수익률 대 산업: 1TB0은 지난 1년 동안 -1%의 수익을 기록한 German Biotechs 산업보다 저조한 성과를 냈습니다.수익률 대 시장: 1TB0은 지난 1년 동안 2.7%를 기록한 German 시장보다 저조한 성과를 냈습니다.주가 변동성Is 1TB0's price volatile compared to industry and market?1TB0 volatility1TB0 Average Weekly Movement6.6%Biotechs Industry Average Movement6.3%Market Average Movement5.2%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.6%안정적인 주가: 1TB0는 지난 3개월 동안 German 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: 1TB0의 주간 변동성(7%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트20091Jakob Bendtsenwww.strategic-partners.dk전략적 파트너 A/S는 별다른 사업을 영위하고 있지 않습니다. 이전에는 신경 퇴행성 희귀 질환 치료를 위한 치료제 개발에 종사했습니다. 이 회사는 이전에는 Orphazyme A/S로 알려졌으며 2024년 10월에 전략적 파트너 A/S로 사명을 변경했습니다.더 보기Strategic Partners A/S 기초 지표 요약Strategic Partners의 순이익과 매출은 시가총액과 어떻게 비교됩니까?1TB0 기초 통계시가총액€3.91m순이익 (TTM)€180.20k매출 (TTM)€40.67k21.7x주가수익비율(P/E)96.0x주가매출비율(P/S)1TB0는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표1TB0 손익계산서 (TTM)매출DKK 304.00k매출원가DKK 0총이익DKK 304.00k기타 비용-DKK 1.04m순이익DKK 1.35m최근 보고된 실적Jun 30, 2026다음 실적 발표일해당 없음주당순이익(EPS)32.29총이익률100.00%순이익률443.09%부채/자본 비율0%1TB0의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/23 15:59종가2026/08/21 00:00수익2026/06/30연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Strategic Partners A/S는 7명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Tazeen AhmadBofA Global ResearchJacob LademannCarnegie Investment Bank ABThomas BowersDanske Bank4명의 분석가 더 보기
Board Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Jakob Have was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공고 • Nov 25Strategic Partners A/S, Annual General Meeting, Apr 28, 2026Strategic Partners A/S, Annual General Meeting, Apr 28, 2026, at 10:00 Romance Standard Time.
공고 • Sep 17Strategic Partners A/S Revises Earnings Guidance for the Fiscal Year 2025Strategic Partners A/S revised earnings guidance for the fiscal year 2025. Based on the first half of the year the company changes its outlook from previously an operating loss in the range of DKK -3 to -4 million to DKK -2 to -3 million.
공고 • Jan 10Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP).Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025. As part of acquisition, 2,327,058 shares were acquired. Stockslatten AB completed the acquisition of 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025.
공고 • Dec 27Strategic Partners A/S, Annual General Meeting, Mar 26, 2025Strategic Partners A/S, Annual General Meeting, Mar 26, 2025.
New Risk • Sep 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€6.71m market cap, or US$7.47m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).
Board Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Jakob Have was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공고 • Nov 25Strategic Partners A/S, Annual General Meeting, Apr 28, 2026Strategic Partners A/S, Annual General Meeting, Apr 28, 2026, at 10:00 Romance Standard Time.
공고 • Sep 17Strategic Partners A/S Revises Earnings Guidance for the Fiscal Year 2025Strategic Partners A/S revised earnings guidance for the fiscal year 2025. Based on the first half of the year the company changes its outlook from previously an operating loss in the range of DKK -3 to -4 million to DKK -2 to -3 million.
공고 • Jan 10Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP).Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025. As part of acquisition, 2,327,058 shares were acquired. Stockslatten AB completed the acquisition of 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025.
공고 • Dec 27Strategic Partners A/S, Annual General Meeting, Mar 26, 2025Strategic Partners A/S, Annual General Meeting, Mar 26, 2025.
New Risk • Sep 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€6.71m market cap, or US$7.47m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).
New Risk • Sep 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (€5.02m market cap, or US$5.62m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding).
New Risk • Mar 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€5.68m market cap, or US$6.13m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
Board Change • Mar 11No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Jakob Have is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
공고 • Feb 22Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024. Orphazyme informed CombiGene that they in total have acquired approximately 10% of the outstanding shares in CombiGene, which makes Orphazyme one of the larger shareholders in the Company. Orphazyme A/S (CPSE:ORPHA) completed the acquisition of an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024.
공고 • May 31+ 2 more updatesOrphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFOOrphazyme A/S announced that the board of directors and CFO Anders Fink Vadsholt has entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023.
공고 • May 18Orphazyme A/S Announces Board ChangesOrphazyme A/S announced that during the Annual General Meeting on May 17, 2023, Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacy as members of the Board of Directors. Michael Schlomo Gabriely Hove, Jakob Færch Bendtsen and Jakob Alsted Have were elected as new members of the Board of Directors by the general meeting.
공고 • Dec 06+ 1 more updateOrphazyme A/S to Report Fiscal Year 2022 Final Results on Mar 28, 2023Orphazyme A/S announced that they will report fiscal year 2022 final results on Mar 28, 2023
공고 • Sep 26Orphazyme A/S Revises Earnings Guidance for the Year 2022Orphazyme A/S revised earnings guidance for the year 2022. The Company has decided to adjust its outlook for 2022, as published on June 7, 2022. The change is driven by the separation of activities into continuing and discontinued operations. The discontinued activities are related to the sale of assets to KemPharm A/S. The continuing business activities are the limited ongoing operational business activities with only two employees. For the full-year 2022, the company anticipates a loss from continuing operations in the range DKK 40 – 45 million and a positive result from discontinued operations relating to the Sale of Assets to KemPharm of DKK 87.4 million (previously operating profit in the range DKK 10 – 30 million).
Breakeven Date Change • Mar 01Forecast to breakeven in 2024The 3 analysts covering Orphazyme expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr.46.7m in 2024. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 4 analysts covering Orphazyme expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr.187.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Executive Departure • Jul 06Independent Director Martijn Kleijwegt has left the companyOn the 30th of June, Martijn Kleijwegt's tenure as Independent Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Martijn's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.
Executive Departure • Jul 06Independent Director Remi P. Droller has left the companyOn the 30th of June, Remi P. Droller's tenure as Independent Director ended after 6.5 years in the role. We don't have any record of a personal shareholding under Remi P.'s name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.
Executive Departure • Jul 06Independent Director Anders Hedegaard has left the companyOn the 30th of June, Anders Hedegaard's tenure as Independent Director ended after 3.6 years in the role. As of March 2021, Anders still personally held 15.68k shares (€177k worth at the time). A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.
Executive Departure • Mar 27Independent Director has left the companyOn the 25th of March, Sten Verland's tenure as Independent Director ended after 10.3 years in the role. We don't have any record of a personal shareholding under Sten's name. A total of 2 executives have left over the last 12 months.
Is New 90 Day High Low • Jan 14New 90-day high: €10.56The company is up 12% from its price of €9.46 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Dec 15New 90-day low: €7.41The company is down 33% from its price of €10.98 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 21New 90-day low: €8.67The company is down 37% from its price of €13.76 on 23 July 2020. The German market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
공고 • Sep 30Orphazyme A/S has completed a Follow-on Equity Offering in the amount of $83.777606 million.Orphazyme A/S has completed a Follow-on Equity Offering in the amount of $83.777606 million. Security Name: American Depositary Share Security Type: Depositary Receipt (Common Stock) Securities Offered: 3,966,146 Price\Range: $11 Discount Per Security: $0.77 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,650,000 Price\Range: $11 Discount Per Security: $0.77 Transaction Features: New Market Listing; Sponsor Backed Offering
공고 • Sep 26Orphazyme A/S Provides Update on Previously Announced Global OfferingOrphazyme A/S announced an update on its previously announced global offering. On September 24, 2020, the Company received a filing communication from the U.S. Food and Drug Administration in connection with its new drug application for arimoclomol for the treatment of Niemann-Pick disease Type C. The FDA letter follows acceptance on a Priority Review basis by the FDA of the Company’s NDA for arimoclomol in NPC and the FDA’s establishment of the Prescription Drug User Fee Act target action date of March 17, 2021. The Company’s receipt of the filing communication does not impact the FDA’s acceptance of the Company’s NDA, the target PDUFA action date or the FDA’s Priority Review determination. In accordance with applicable securities laws, the Company intends to amend the registration statement on Form F-1 on file with the U.S. Securities and Exchange Commission on September 25, 2020. The Company has also updated its proposed timing for the global offering referenced in the company announcement no. 51/2020, dated September 21, 2020, and now intends to price the global offering and announce the subscription price on September 28, 2020, subject to market conditions, and to settle the global offering on October 1, 2020. The Company also reported that the book for the global offering is fully covered as of September 24, 2020. The ordinary shares of the Company are currently listed on Nasdaq Copenhagen under the symbol ”ORPHA”. In connection with the global offering, Nasdaq has approved the listing of the American Depositary Shares in the U.S. under the symbol "ORPH". A registration statement on Form F-1 relating to the proposed sale of the Securities has been filed with the SEC but has not yet become effective. The Securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement on Form F-1 becomes effective. The Board has not yet determined whether to complete the global offering. Even if the Board determines to complete the global offering, the global offering may not be consummated. Neither the timing, number of shares, number of ordinary underlying shares of Orphazyme, nor the price of the ADSs and thereby the price of the underlying shares has been finally determined. If consummated, the final price for the ordinary shares and ADSs will be determined following a book-building process.
Is New 90 Day High Low • Sep 26New 90-day low: €9.92The company is down 18% from its price of €12.14 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
공고 • Sep 22Orphazyme A/S Elects Carrolee Barlow as Board of DirectorOrphazyme A/S elected Carrolee Barlow as new member of the Board of Directors, Extraordinary General Meeting held on September 21, 2020.
